| Ivabradine: recent and potential applications in clinical practice. | |
| | |
MedLine Citation:
|
PMID: 21254949 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
published data indicate that heart rate is an independent strong predictor of cardiovascular and all-cause mortality in men and women of all ages, with and without cardiovascular disease, including atherosclerosis, ventricular arrhythmias, and left ventricular dysfunction. Ivabradine is a pure heart-rate-lowering agent with well-documented antianginal and anti-ischemic properties comparable to well-established anti-anginal agents. AREAS COVERED: this short review explores recent results with ivabradine, a new medication that lowers heart rate by selectively inhibiting the I (f) current. This review also describes future potential applications. EXPERT OPINION: measurement of heart rate represents an important component of the assessment of patients with coronary artery disease and chronic heart failure, and should be viewed in the same light as other risk factors, because a high heart rate has direct detrimental effects not only on myocardial ischemia but also on the progression of atherosclerosis, ventricular arrhythmias and left ventricular function. Ivabradine has anti-ischemic and antianginal efficacy equivalent to that of β-blockers and calcium channel antagonists in the treatment of chronic stable angina pectoris. Recently ivabradine has been shown to improve cardiac outcomes in stable coronary artery disease and left ventricular systolic dysfunction in patients who have heart rates of ≥ 70 bpm and in patients with stable angina. |
| | |
Authors:
|
Graziano Riccioni |
Related Documents
:
|
20884419 - Subtle myocardial damage associated with diagnostic coronary angiography alone. 19251459 - Analysis of cardiac troponins and creatine kinase mb in cerebrospinal fluid in medicole... 20380359 - Cardiac troponin t release and inflammation demonstrated in marathon runners. 21416189 - Contribution of comorbidities to functional impairment is higher in heart failure with ... 10451239 - Clinical application of markers of cardiac injury: basic concepts and new considerations. 1457309 - Apparent elevation of serum ck-mb not due to acute myocardial infarction. 1106949 - Time constant of thermistors and its role in thermodilution methods. 14680629 - Heart of glass regulates the concentric growth of the heart in zebrafish. 12641019 - Transcatheter closure of intracardiac shunts. |
Publication Detail:
|
Type: Journal Article; Review |
Journal Detail:
|
Title: Expert opinion on pharmacotherapy Volume: 12 ISSN: 1744-7666 ISO Abbreviation: Expert Opin Pharmacother Publication Date: 2011 Feb |
Date Detail:
|
Created Date: 2011-01-24 Completed Date: 2011-04-20 Revised Date: 2013-05-20 |
Medline Journal Info:
|
Nlm Unique ID: 100897346 Medline TA: Expert Opin Pharmacother Country: England |
Other Details:
|
Languages: eng Pagination: 443-50 Citation Subset: IM |
Affiliation:
|
Intensive Cardiology Care Unit, San Camillo De Lellis Hospital, Manfredonia (FG), Italia. griccioni@hotmail.com |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Angina Pectoris
/
drug therapy,
physiopathology Animals Benzazepines / pharmacology* Cardiovascular Agents / pharmacology* Cardiovascular Diseases / drug therapy, physiopathology Coronary Artery Disease / drug therapy, physiopathology Female Heart Rate / drug effects* Humans Male Risk Factors Ventricular Dysfunction, Left / drug therapy, physiopathology |
| Chemical | |
Reg. No./Substance:
|
0/Benzazepines; 0/Cardiovascular Agents; 155974-00-8/ivabradine |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Pharmacotherapy for treatment-refractory schizophrenia.
Next Document: Imiquimod 3.75% cream (Zyclara) for the treatment of actinic keratoses.